Navigation Links
Dong-A PharmTech Co., Ltd. Announces Start of Phase III Trials for Udenafil, Its New Erectile Dysfunction Drug Under Development
Date:11/4/2009

SEOUL, Korea, Nov. 4 /PRNewswire/ -- Dong-A PharmTech Co. Ltd., announced that its U.S. partner, Warner Chilcott plc, has initiated two, phase III trials for udenafil, a new long acting drug under development for erectile dysfunction (ED). Each randomized, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of udenafil, an orally administered selective inhibitor of phosphodiesterase versus placebo. The trials will be conducted in 80 sites in the U.S. and will enroll approximately 1,120 subjects with ED.

Mr. Dong Hyun Park, President & CEO of Dong-A PharmTech, commented that, "We are extremely pleased to be entering the last phase of our udenafil development program in the United States with our partner Warner Chilcott. We are aiming to complete the remaining clinical trials for the udenafil erectile dysfunction program in the U.S. and European Union as well as most other major markets within 2 years. In addition, based on recent positive meetings with the USFDA, we anticipate initiating Phase 2b clinical trials which will evaluate the safety and efficacy of udenafil for benign prostatic hyperplasia (BPH) and pulmonary arterial hypertension (PAH)".

Udenafil was approved for marketing by the Korean Food and Drug Administration in November of 2005 and launched commercially in Korea in early 2006 under the trade name Zydena®. From 2006 to the first half of 2009, over 1,000,000 prescriptions for more than 6 million tablets of Zydena® were written for men with erectile dysfunction in Korea.

Zydena was also approved for marketing by the Russian Food and Drug Administration in July of 2008 and launched commercially in Russia in March 2009 under the trade name Zydena®.

If approved, udenafil is expected to participate in a growing prescription ED market by offering a long acting and safe product that will compete with Viagra® (Pfizer), Cialis (Lilly) and
'/>"/>

SOURCE Dong-A PharmTech Co. Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
2. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... DIEGO and BOSTON , ... leader in instrument development, custom automation, and contract manufacturing, ... of the Nanopatch™ needle-free drug delivery technology, have been ... development of the Nanopatch Jet Coating Instrument , ... delivery research and product development.  The award was announced ...
(Date:5/29/2015)... SAN DIEGO , May 29, 2015 /PRNewswire/ ... single cell sequencing data, from metastatic castrate resistant ... of the American Society for Clinical Oncology. This ... no cell left behind™ platform to ... study revealed that late stage patients have heterogeneous ...
(Date:5/28/2015)... Lilly and Company (NYSE: LLY ) announced today the ... up to $1.6 billion aggregate principal amount of certain of ... tendered, and did not validly withdraw, their notes on or ... time, on May 27, 2015 (the early tender date), and ... receive the total consideration. The total consideration for each series ...
Breaking Medicine Technology:Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... 2011 The Rottenstein Law Group, which represents clients with ... manufactured and sold by DePuy Orthopaedics, is fully in support ... of metal-on-metal joint implants. At a new set ... U.S. Food and Drug Administration states the following: ...
... VILLAGE, Nev., March 7, 2011   PDL BioPharma, ... guidance for the first quarter ending March 31, 2011 of ... million for the first quarter of 2010, an expected 34 ... the $10 million settlement received from UCB Pharma S.A. (UCB) ...
Cached Medicine Technology:Rottenstein Law Group Applauds New Efforts of U.S. FDA to Look More Carefully at Metal-on-Metal Implants After DePuy Recall 2PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 2PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 3PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 4
(Date:5/29/2015)... May 29, 2015 Johnson & ... a confidential Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement ... due to his use of the antipsychotic medication. ... selected for the third bellwether trial to involve ... litigation underway in Pennsylvania’s Philadelphia Court of Common ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The ... the graduates of its Advanced Training Program (ATP) ... who fill roles in their health care organization ... theory and methodology of continuous quality improvement in ... sister-program to Dr. Brent James’ internationally recognized Advanced ...
(Date:5/29/2015)... A group of doctors have discovered “The Cure ... to teach this “new math” to children in early childhood ... by the recent implementation of Common Core Math in classrooms ... Core is now a reality in children’s classrooms in 44 ... seeking ways to improve common core math training for their ...
(Date:5/29/2015)... 2015 World Patent Marketing, a vertically ... it has signed a 10 year licensing agreement for ... to let people learn about any topic and get ... "This is an exciting day for World Patent Marketing ... Cooper, CEO and Creative Director of World Patent Marketing, ...
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 ... Utah, recently partnered with Stratus Video ... which will facilitate better communication and timely ... (LEP) and hearing loss. Stratus’ video remote ... in-house translators, enabling staff to quickly access ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:HORNE LLP’s Healthcare Delivery Institute Graduates Class from the Advanced Training Program 2Health News:Doctors Discover a Cure for the Common Core 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4
... , ... ... ... , ...
... ... ... ... ...
... MS Awareness Week March 8-14 is the ... someone is newly diagnosed every hour of every day. Supported by a Congressional resolution, this year ... world free of MS! , ... March 8, 2010 -- MS Awareness Week March 8-14 is the time for the nation ...
... , ... ... ... ...
... ... pictures that are better than anything that’s come before. With the new technology they’ve developed, ... in the heart and the major arteries around it. , ... Madison, WI (PRWEB) March 8, 2010 -- What does the ...
... ... announced today they have been named as the preferred distributor of Gendron bariatric care ... Gendron bariatric care medical equipment to healthcare professionals who wish to purchase or lease. ... Issaquah, WA. ...
Cached Medicine News:Health News:World Cocoa Foundation Launches Cocoa Livelihoods Program in Nigeria 2Health News:World Cocoa Foundation Launches Cocoa Livelihoods Program in Nigeria 3Health News:World Cocoa Foundation Launches Cocoa Livelihoods Program in Nigeria 4Health News:World Cocoa Foundation Launches Cocoa Livelihoods Program in Nigeria 5Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 2Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 3Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 4Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 5Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 6Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 7Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 2Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 3Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 4Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 5Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 6Health News:I'm Not Crazy...I'm Just Not You 2Health News:I'm Not Crazy...I'm Just Not You 3Health News:I'm Not Crazy...I'm Just Not You 4Health News:I'm Not Crazy...I'm Just Not You 5Health News:I'm Not Crazy...I'm Just Not You 6Health News:Heart Aflutter? Remarkable New Images Show What it Looks Like in 4-D 2Health News:Heart Aflutter? Remarkable New Images Show What it Looks Like in 4-D 3Health News:QuickMedical Launches New Line of Medical Equipment for Bariatric Care 2Health News:QuickMedical Launches New Line of Medical Equipment for Bariatric Care 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: